In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe. Some background Treatment to decrease the male hormones,...Read More
Prostate cancer Posts on Medivizor
Can the neutrophil to lymphocyte ratio predict outcome in enzalutamide-treated prostate cancer patients?
In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide. Some background Treatment for metastatic...Read More
In a nutshell This study investigated whether the likelihood of developing skeletal related events (SREs) could be determined depending on the site of metastasis at diagnosis and other factors in older patients with prostate cancer. The study concluded that the likelihood of developing an SRE was similar among different sites of metastasis, except...Read More
In a nutshell The aim of this study was to investigate if circulating tumor cells (CTC) levels in the blood could be used to determine the outcome for metastatic castration resistant prostate cancer patients. This study concluded that CTC levels could be used to predict survival in these patients. Some background Treatment for metastatic...Read More
In a nutshell The authors aimed to determine the influence of biopsy timing on prostate cancer reclassification during active surveillance. The authors concluded that the timing of the first biopsy was not related to an increased risk of cancer reclassification, but prostate specific antigen (PSA) and body mass index (BMI – measured based...Read More
In a nutshell The authors aimed to determine how pre-operative blood fat levels affect the outcome in men with localized prostate cancer undergoing prostate surgery. The authors conclude that blood fats can cause adverse effects and act as an independent outcome predictor in men with prostate cancer following surgery. Some background...Read More
In a nutshell The authors aimed to determine the impact of obesity on patient outcomes following open and minimally invasive prostate surgery. The authors concluded that obesity has a large impact on complication rates in patients who received minimally invasive surgery compared to patients who received open prostate surgery. Some...Read More
In a nutshell The authors aimed to identify the recommended treatments for prostate cancer in men over the age of 70 years. The authors concluded that treatments for local and advanced prostate cancer in elderly men should be individualized, with focus on the health of the patient, to determine the appropriate treatment course. Some background...Read More
In a nutshell The authors aimed to determine guidelines for the treatment of relapsing, metastatic, and hormone-resistant prostate cancer. Some background Metastatic prostate cancer (advanced cancer) is cancer that has spread outside of the prostate to other organs of the body, despite treatment. Hormone therapy is the standard...Read More
In a nutshell The authors aimed to determine how anxiety and uncertainty affects men with prostate cancer who are undergoing active surveillance. The authors concluded that uncertainty and urinary complications promote anxiety in men on active surveillance for prostate cancer. They also recommend patient education and management of urinary...Read More
Can sentinel lymph node dissection be used to identify patients who could benefit from further therapy?
In a nutshell The aim of the study was to examine if sentinel lymph node dissection (SLND) could be used to select patients with prostate cancer who would benefit from further pelvic radiation therapy and long-term androgen deprivation therapy (ADT). It was concluded that SLND could be used as a tool to determine whether patients should have more...Read More
In a nutshell The aim of this study was to compare the heath related quality of life (HRQOL) of patients treated with enzalutamide (Xtandi) or bicalutamide (Casodex). It was concluded that enzalutamide led to a better HRQOL in patients with metastatic castration resistant prostate cancer when compared...Read More